PL3697819T3 - Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1 - Google Patents
Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1Info
- Publication number
- PL3697819T3 PL3697819T3 PL18807145.0T PL18807145T PL3697819T3 PL 3697819 T3 PL3697819 T3 PL 3697819T3 PL 18807145 T PL18807145 T PL 18807145T PL 3697819 T3 PL3697819 T3 PL 3697819T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- ovarian cancer
- ovarian
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574073P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/056442 WO2019079549A1 (en) | 2017-10-18 | 2018-10-18 | TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3697819T3 true PL3697819T3 (pl) | 2023-03-06 |
Family
ID=64402251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18807145.0T PL3697819T3 (pl) | 2017-10-18 | 2018-10-18 | Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047416A1 (https=) |
| EP (2) | EP4194470A1 (https=) |
| JP (3) | JP7308190B2 (https=) |
| KR (1) | KR20200070341A (https=) |
| CN (1) | CN111315783A (https=) |
| AU (1) | AU2018351007B2 (https=) |
| CA (1) | CA3078430A1 (https=) |
| ES (1) | ES2938652T3 (https=) |
| PL (1) | PL3697819T3 (https=) |
| PT (1) | PT3697819T (https=) |
| SI (1) | SI3697819T1 (https=) |
| WO (1) | WO2019079549A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3747906A1 (en) | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| SI4177270T1 (sl) | 2017-10-18 | 2024-10-30 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti cd47 |
| AU2019218271B2 (en) | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
| US20220289848A1 (en) * | 2019-05-17 | 2022-09-15 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| TWI855236B (zh) * | 2020-02-28 | 2024-09-11 | 大陸商南京聖和藥業股份有限公司 | 抗cd47/抗pd-l1抗體及其應用 |
| JP7627349B2 (ja) * | 2021-01-08 | 2025-02-05 | 北京韓美薬品有限公司 | 抗ｐｄ－ｌ１／抗ｃｄ４７天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| PT2970493T (pt) | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| CN117138060A (zh) * | 2014-10-07 | 2023-12-01 | 免疫医疗公司 | 抗体-药物缀合物的新辅助剂用途 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017019767A1 (en) * | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| BR112018005322A2 (pt) * | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| US20190290759A1 (en) * | 2015-12-28 | 2019-09-26 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| WO2017127707A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
-
2018
- 2018-10-18 PL PL18807145.0T patent/PL3697819T3/pl unknown
- 2018-10-18 CA CA3078430A patent/CA3078430A1/en active Pending
- 2018-10-18 EP EP22207465.0A patent/EP4194470A1/en active Pending
- 2018-10-18 WO PCT/US2018/056442 patent/WO2019079549A1/en not_active Ceased
- 2018-10-18 SI SI201830820T patent/SI3697819T1/sl unknown
- 2018-10-18 CN CN201880071877.6A patent/CN111315783A/zh active Pending
- 2018-10-18 KR KR1020207014146A patent/KR20200070341A/ko not_active Ceased
- 2018-10-18 EP EP18807145.0A patent/EP3697819B1/en active Active
- 2018-10-18 AU AU2018351007A patent/AU2018351007B2/en active Active
- 2018-10-18 PT PT188071450T patent/PT3697819T/pt unknown
- 2018-10-18 ES ES18807145T patent/ES2938652T3/es active Active
- 2018-10-18 JP JP2020521860A patent/JP7308190B2/ja active Active
- 2018-10-18 US US16/756,790 patent/US20210047416A1/en not_active Abandoned
-
2022
- 2022-11-22 JP JP2022186496A patent/JP7474827B2/ja active Active
-
2024
- 2024-01-12 JP JP2024003136A patent/JP2024024121A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019079549A1 (en) | 2019-04-25 |
| EP3697819A1 (en) | 2020-08-26 |
| CA3078430A1 (en) | 2019-04-25 |
| EP3697819B1 (en) | 2022-11-16 |
| JP2023014162A (ja) | 2023-01-26 |
| AU2018351007A1 (en) | 2020-05-21 |
| AU2018351007B2 (en) | 2024-05-16 |
| PT3697819T (pt) | 2023-02-20 |
| JP7474827B2 (ja) | 2024-04-25 |
| KR20200070341A (ko) | 2020-06-17 |
| CN111315783A (zh) | 2020-06-19 |
| ES2938652T3 (es) | 2023-04-13 |
| EP4194470A1 (en) | 2023-06-14 |
| JP7308190B2 (ja) | 2023-07-13 |
| US20210047416A1 (en) | 2021-02-18 |
| SI3697819T1 (sl) | 2023-01-31 |
| JP2024024121A (ja) | 2024-02-21 |
| JP2021500336A (ja) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| PT3697819T (pt) | Tratamento de cancro do ovário com anti-cd47 e anti-pd-l1 | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| IL261959A (en) | Cancer treatment with tg02 | |
| EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
| ZA201802481B (en) | Novel biomarkers and methods of treating cancer | |
| IL262342A (en) | Cancer treatment methods | |
| SG11202005163PA (en) | Methods of treating cancer | |
| SG10202103525UA (en) | Cancer biomarkers and methods of use | |
| IL269123A (en) | Methods of treating cancer | |
| IL255541A (en) | Cabazitaxel and its use for treating cancer | |
| GB201609402D0 (en) | Materials and methods for treating cancer | |
| SG11202002529TA (en) | Ovarian cancer biomarker and use thereof | |
| GB201503371D0 (en) | Methods of screening and treatment | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| AU2016904962A0 (en) | Methods of treating cancer and reagents therefor | |
| GB201522615D0 (en) | Methods of screening and treatment | |
| GB201505437D0 (en) | Methods of screening and treatment | |
| GB201503392D0 (en) | Methods of screening and treatment |